These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 9156935

  • 1. [An effect of chromatographic fraction ultrafiltrate of plasma on aggregation of blood platelets in patients with chronic uremia].
    Popławski A, Myśliwiec M.
    Pol Merkur Lekarski; 1996 Oct; 1(4):246-8. PubMed ID: 9156935
    [Abstract] [Full Text] [Related]

  • 2. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A, Myśliwiec M, Soszka J.
    Pol Tyg Lek; 1996 Oct; 45(40-41):810-3. PubMed ID: 2096374
    [Abstract] [Full Text] [Related]

  • 3. [Effect of ultrafiltrates in plasma from patients with chronic uremia on platelet aggregation].
    Myśliwiec M, Popławski A, Soszka J.
    Pol Tyg Lek; 1996 Oct; 46(4-5):76-8. PubMed ID: 1845699
    [Abstract] [Full Text] [Related]

  • 4. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
    Elshamaa MF, Elghoroury EA, Helmy A.
    Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
    [Abstract] [Full Text] [Related]

  • 5. "In vitro" inhibition of platelet aggregation by uremic middle molecules.
    Gallice P, Fournier N, Crevat A, Saingra S, Frayssinet R, Murisasco A, Sicardi F.
    Biomedicine; 1980 Jun; 33(6):185-8. PubMed ID: 7213919
    [Abstract] [Full Text] [Related]

  • 6. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa.
    Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF.
    Am J Hematol; 2006 Dec; 81(12):915-26. PubMed ID: 16917914
    [Abstract] [Full Text] [Related]

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J, Klahr S, Bricker NS.
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [Abstract] [Full Text] [Related]

  • 9. The binding of 125I-fibrinogen to blood platelets in patients with chronic uraemia.
    Komarnicki M, Zozulińska M, Zawilska K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987 Feb; 114(5):638-41. PubMed ID: 2448203
    [Abstract] [Full Text] [Related]

  • 10. [Altered circadian rhythm of platelet aggregation in patients on longterm hemodialysis].
    Rydzewski A, Małyszko J, Borawski J, Pawlak D, Adamcewicz K, Buczko W, Myśliwiec M.
    Przegl Lek; 1997 Feb; 54(3):167-70. PubMed ID: 9297192
    [Abstract] [Full Text] [Related]

  • 11. [Modification of uremic thrombocytopathy by hemodialysis].
    Frick U, Frick G, Vitu J, Wiedenhöft I.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983 Feb; 110(2):309-13. PubMed ID: 6194064
    [Abstract] [Full Text] [Related]

  • 12. [Activation of blood platelets and the plasma coagulation system in patients with chronic uremia].
    Dmoszyńska-Giannopoulou A, Ksiazek A, Baran E, Pachucki Z.
    Pol Tyg Lek; 1987 Jul 27; 42(30):915-7. PubMed ID: 3671183
    [No Abstract] [Full Text] [Related]

  • 13. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R, Emond C, Claret G, Branger B, Mion H, Mion C.
    Artif Organs; 1981 Jul 27; 4 Suppl():177-83. PubMed ID: 7295089
    [Abstract] [Full Text] [Related]

  • 14. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L, Kálmán K, Hauck M, Kakuk G.
    Allerg Immunol (Leipz); 1979 Jul 27; 25(3):211-7. PubMed ID: 162030
    [Abstract] [Full Text] [Related]

  • 15. [Effect of uremic plasma fractions of different molecular sizes on the filterability of red blood cells].
    Eggert W, Scigalla P, Noack C, Devaux S, Wolf S.
    Z Urol Nephrol; 1981 May 27; 74(5):391-9. PubMed ID: 7269824
    [Abstract] [Full Text] [Related]

  • 16. Determination of endogenous middle molecules in normal and uremic body fluids.
    Fürst P, Zimmerman L, Bergström J.
    Clin Nephrol; 1976 Apr 27; 3(2):178-88. PubMed ID: 1277595
    [Abstract] [Full Text] [Related]

  • 17. Isolation and partial characterization of platelet aggregation inhibitors in the blood of dialyzed patients.
    Mabuchi H, Nakahashi H.
    Nephron; 1983 Apr 27; 35(2):112-5. PubMed ID: 6621755
    [Abstract] [Full Text] [Related]

  • 18. Peak 7c and creatinine weekly clearances in various dialytic procedures.
    Icardi A, Carozzi S, Trasforini D, Moriero E, Lamperi S.
    Life Support Syst; 1983 Apr 27; 1 Suppl 1():162-5. PubMed ID: 6336401
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM, van Landschoot N, de Smet R.
    Clin Nephrol; 1980 Mar 27; 13(3):109-12. PubMed ID: 7379359
    [Abstract] [Full Text] [Related]

  • 20. Chromatographic analysis of middle molecules in plasma ultrafiltrates of uraemic patients.
    Popławski A, Myśliwiec M.
    Nephrol Dial Transplant; 1993 Mar 27; 8(2):188. PubMed ID: 8384345
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.